to the previously established Big Blue ® assay. Genomic DNA isolated from liver, spleen, and lung tissue of control or ethylnitrosourea (ENU)-treated Big Blue ® mice (100 mg/kg i.p., single dose) was packaged into phage (five animals, two packagings per DNA sample) which were simultaneously plated f
Transmission of mutations in the lacI transgene to the offspring of ENU-treated Big Blue® male mice
✍ Scribed by Lois B. Barnett; Rochelle W. Tyl; Barbara S. Shane; Michael D. Shelby; Susan E. Lewis
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 99 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0893-6692
- DOI
- 10.1002/em.10114
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
However, the interpretation of data from transgenic animal assays is sometimes complicated by mutants that appear as sectored mutant lambda plaques. These mutants can form a significant fraction of the mutant plaques [Hayward et al. (1 995): Carcinogenesis 16:2429-24331. Thus, in order to accurately
Big Blue ® mice harbor a recoverable transgene in a lambda/LIZ shuttle vector. In the standard assay, in vivo mutations are measured in the bacterial lacI gene using a labor-intensive color plaque assay. Applying a simpler assay : Proc Natl Acad Sci USA 93:9073-9078], we measured mutations in the la
Big Blue@ (BB) and generic B6C3F1 mice were given one to three i.p. injections of 50 mg/kg benzo[a]pyrene (B[a]P) in DMSO every other day to achieve cumulative doses of 50 to 150 mg/kg. Three weeks after treatment, the mutation frequency at the endogenous hprt gene and lac/ transgene was measured in